

Madrid, February 18, 2026

LABIANA HEALTH, S.A. (hereinafter, the "Company"), in compliance with the provisions of Article 17 of Regulation (EU) No. 596/2014 of the European Parliament and of the Council of April 16, 2014, on market abuse, and in accordance with the provisions of Article 227 of Law 6/2023 of March 17 on Securities Markets and Investment Services, as well as Circular 3/2020 of the BME Growth segment of BME MTF Equity, on information to be provided by companies listed on that segment, hereby makes public the following:

PRIVILEGED INFORMATION

Formalization of syndicated financing

On February 18, 2026, LABIANA HEALTH, S.A. (the "Company") signed a syndicated financing agreement for a maximum amount of €37 million with Deutsche Bank, S.A.E.U. (as lead manager and agent), Institut Català de Finances, Andorra Banc Agrícola Reig, S.A., Caixabank, S.A., and Banco Santander, S.A.

The financing is structured in the following tranches:

- Tranche A: long-term senior repayable loan for €30 million, with a final maturity of up to seven (7) years, mainly intended to refinance existing debt and meet corporate needs
- Tranche B (CapEx): long-term senior amortizable loan in the amount of €4 million, with a final maturity of up to seven (7) years, intended to partially finance the Group's investment plan for the 2026 and 2027 fiscal years.
- Tranche C (RCF): *revolving* credit facility for €3 million, with an initial maturity of three (3) years, extendable up to a maximum total term of seven (7) years, for working capital and operating needs.

In accordance with the provisions of the financing agreement, the effectiveness of the transaction is subject to the approval of a capital increase for a minimum amount of €5 million. The terms and conditions of this capital increase are detailed in the corresponding Inside Information published on this same date.

The financing has the corresponding first-ranking security package and incorporates the usual conditions for this type of financing, including compliance with financial *covenants*, periodic reporting obligations, limitations on distributions to shareholders in any form, including the payment of dividends, during the term of the financing, minimum operating cash balance requirements, and restrictions on taking on additional debt, among other commitments.

Among the main objectives of the transaction are the early repayment of the financing with Miralta Credit Opportunities, S.L. and BSSF II Origination DAC for €25 million, as well as the partial repayment of ICO loans, within the framework of the execution of the Company's financial plan. The cancellation of the pre-existing financing and its replacement with the syndicated financing described above allows for the establishment of a new progressive



repayment schedule, with extended maturities, as well as the elimination of instruments with potential dilutive effects associated with the previous structure.

Likewise, the agreed financing includes resources earmarked for the execution of the investment plan (CapEx) and a working capital line, configuring a financial structure aligned with the Company's anticipated operating and development needs.

In compliance with the provisions of Circular 3/2020 of the BME MTF Equity, it is expressly stated that the information communicated herein has been prepared under the sole responsibility of the Company and its administrators.

We remain at your disposal for any clarifications you may require.

Sincerely,

Mr. Manuel Ramos Ortega
Chief Executive Officer
LABIANA HEALTH, S.A.